Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 5/20 | 0.34 |
| ▸ | CCKBR | P32239 | 5/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16478843 | 1.00 | GLP1R (0.45) | GLP1RFOLH1ALBCA9CCKAR | |
| SCHEMBL15849999 | 1.00 | GLP1R (0.45) | GLP1RFOLH1ALBCA9CCKAR | |
| SCHEMBL20567326 | 0.94 | GLP1R (0.45) | GLP1RFOLH1ALBCCKARCCKBR | |
| SCHEMBL20567323 | 0.94 | GLP1R (0.45) | GLP1RFOLH1ALBCCKARCCKBR | |
| SCHEMBL16180948 | 0.93 | GLP1R (0.47) | GLP1RFOLH1ALBCA9CCKAR | |
| SCHEMBL16478775 | 0.93 | GLP1R (0.45) | GLP1RFOLH1ALBCA9CCKAR | |
| SCHEMBL24734313 | 0.90 | GLP1R (0.51) | GLP1RCCKARCCKBR | |
| SCHEMBL16093453 | 0.90 | GLP1R (0.44) | GLP1RCCKARCCKBR | |
| SCHEMBL16142393 | 0.90 | GLP1R (0.42) | GLP1RCCKARCCKBRGLO1 | |
| SCHEMBL16180970 | 0.90 | GLP1R (0.46) | GLP1RCCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305994-A1 | Antagonistic DR3 Ligands | NOVO NORDISK AS (DK) | 2017-10-26 | — | — | US | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305994-A1 | Antagonistic DR3 Ligands | ACKR3, FPR3, FCGR3B | GLP1R 1320/4885FOLH1 2136/4885ALB 3843/4885 |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | GLP1R 101/4885FOLH1 469/4885ALB 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.